Please assess the completion status of the following clinical trial:

Trial Title: First Line Therapy for High Risk Acute GVHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. diagnosed with hematological diseases.~2. Have undergone first allogeneic hematopoietic stem cell transplantation (allo-HSCT) from any donor source using bone marrow, peripheral blood stem cells, or cord blood for hematologic malignancies.~3. new onset of grade II\~IV aGVHD or intermediate or high risk aGVHD (based on ST2, REG3a, other experimental objects) within 100 days post-transplantation.~Exclusion Criteria:~1. recipients of second allogeneic stem cell transplant.~2. acute GVHD induced by donor lymphocyte infusion, interferon.~3. received first line aGVHD treatment before enrollment.~4. overlap GVHD syndrome.~5. pregnant or breast-feeding women.~6. absolute neutrophil count (ANC) \<0.5×10e9/L or platelet count (PLT) \< 20×10e9/L~7. Serum creatinine \> 2.0 mg/dL or creatinine clearance \< 40 mL/min measured or calculated by Cockroft-Gault equation.~8. uncontrolled infection~9. human immunodeficiency virus infection~10. active hepatitis b virus, hepatitis C virus infection and need antivirus treatment.~11. Subjects with evidence of relapsed primary disease, or subjects who have been treated for relapse after the allo-HSCT was performed, or graft rejection.~12. allergic history to Janus kinase inhibitors.~13. Severe organ dysfunction unrelated to underlying GVHD, including:~    Cholestatic disorders or unresolved veno-occlusive disease of the liver (defined as persistent bilirubin abnormalities not attributable to GVHD and ongoing organ dysfunction).~    Clinically significant or uncontrolled cardiac disease including unstable angina, acute myocardial infarction within 6 months from Day 1 of study drug administration, New York Heart Association Class III or IV congestive heart failure, circulatory collapse requiring vasopressor or inotropic support, or arrhythmia that requires therapy.~    Clinically significant respiratory disease that requires mechanical ventilation support or 50% oxygen.~14. Received Janus kinase inhibitor therapy after allo-HSCT for any indication.~15. Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib combined with Corticosteroids (Type: EXPERIMENTAL): Participants began oral administration of ruxolitinib at 5 mg QD; Methylprednisolone: 1mg/kg/d , iv or iv gtt for at leas 5 days, then taper according to the clinical response.
- Corticosteroids (Type: ACTIVE_COMPARATOR): Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 1 week, then taper according to the clinical response.

Based on this trial design, predict the completion outcome and termination type (if applicable).